Clinical studies have shown that the most common side effect is a slight reaction at the site of injection in the form of redness, and sometimes swelling. Clinical studies have shown that, one hour after injection, the incidence of at least one moderate or severe local skin reaction per treatment cycle was 12% in 4 patients treated with<unk>  and 25% in patients treated subcutaneously with a GnRH agonist. The local reactions generally disappear within 4 hours after administration. Other reported side effects are some that are known to be associated with ovarian hyperstimulation, including gynecological abdominal pain, headache, vaginal bleeding, nausea, and gastrointestinal abdominal pain. In some rare cases, less than 1 user in 10,000, hypersensitivity to<unk>  can cause anaphylactoid reactions, most likely due to allergy. Birth defects A follow-up analysis for<unk>  done by the Marketing Authorisation Holder compared the number of congenital malformations between individuals whose mothers were treated with<unk>  compared with individuals whose mothers were treated with a GnRH agonist. The total number of congenital malformations was higher in the<unk>  group than in the GnRH agonist group (7.6% vs. 5.5%). This falls within the range for the normal incidence of congenital malformations, and current data do not suggest that<unk>  increases the incidence of congenital malformations or anomalies. No important differences in the frequency of ectopic pregnancies and miscarriage were noted with the use of<unk> .
Ganirelix
Cobicistat
Migalastat
Oprelvekin
Vosoritide
Pravastatin
Fluvastatin
Lovastatin